Devices

 News Release - March 25, 2008

Medipattern Expands Global Base With B-CAD(TM) Installation in Austria

B-CAD helps determine the edge of the lesion, a key indicator of Breast Cancer

TORONTO, ONTARIO--(Healthcare Sales & Marketing Network)--Mar 25, 2008 -- Attention: Business/Financial Editors: The Medipattern Corporation (CDNX:MKI.V ), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to aid physicians in making better informed biopsy decisions and to permit a higher standard of care for the millions of patients at risk of cancer, is pleased to announce the installation of B-CAD 2.2 at General Hospital in Salzburg, Austria. Austria initiated a province wide breast ultrasound-screening program for higher risk patients in January 2008 as a pilot program in preparation for countrywide adoption. The program focuses on higher risk patients and those with mammographically dense breast tissue, which is imaged more effectively with breast ultrasound technology.

"B-CAD has a true strength in segmenting or outlining the edge of the lesion. The diagnostic decision differentiating benign from malignant findings is largely based upon being able to see and determine the edge of the lesion. Breast lesions can be very small with indistinct boundaries increasing the difficulty in correctly identifying them," said Christian Weismann, MD, Head of the Diagnostic and Interventional Breast Unit, Univ. Inst. of Radiology, General Hospital Salzburg and Head of the Salzburg Breast Screening Program, which is part of the Austrian National Breast Screening Program. "Results can vary between various physicians when lesions are difficult to see. Standardization is very important in ensuring consistent results, which are especially important when establishing a national standard in all breast imaging facilities. B-CAD may be very useful in helping physicians reach a better level of standardization."

B-CAD receives ultrasound images collected on GE Medical Systems Kretz Ultrasound, Voluson E 8 via a direct link to GE Healthcare's Centricity Picture Archiving and Communication System (PACS) integrating both to the device and the PACS. B-CAD further outlines the edge of the lesion and then characterizes the lesion using internationally recognized standards to aid in the diagnostic interpretation assessing the lesion as either probably benign or probably malignant.

"Breast ultrasound has been shown to be more effective in imaging breast cancer in high risk women in numerous studies. Dr. Weismann is dedicated to finding breast cancer earlier for all patients in Austria through pioneering the advanced screening program. Medipattern is pleased to support this goal," said Jeff Collins, CEO and co-founder of Medipattern. "Dr. Weismann is a recognized leader in breast ultrasound imaging and will be lecturing this year in India, China and the United States as well as throughout Europe, and is the author of numerous papers and articles."

Upcoming Events:

Medipattern will participate in the following events:

- Ultrasound Woman's Imaging Conference, April 3 to 6, Boston, MA USA

- China Med Conference, April 10 to 15, Beijing, PRC, exhibiting with partner: Beijing Eastwide

- The Breast Course, April 13 to 16, Quebec City, Quebec, Canada, exhibiting with partner: OSIRIS Imaging, Ltd.

- American Society of Breast Surgeons (ASBS) Annual Meeting, April 30 to May 4, New York City, NY USA, exhibiting with partner Physicians Consultants, Inc.

- Advanced Breast Imaging Symposium, May3 to 4, Ankara, Turkey, exhibiting with partner: Teknikel TIC. VE SAN A.S.

- 33rd National Conference on Breast Cancer, American College of Radiology (ACR) Society of Breast Imaging (SBI), May 8 to 10, Orlando, FL, USA

- The Leading Edge Ultrasound Conference, May 20 to 23, Atlantic City New Jersey, exhibiting with partner: GE Healthcare

- Chicago International Breast Course, September 12 to 15, Chicago, IL, USA

- Radiological Society of North America (RSNA), November 30 to December 5, Chicago, IL, USA

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD(TM) for breast ultrasound and B-CADMRI(TM). Both have received awards for innovation in the industry. The B-CAD products, part of the Company's CADENZA(TM) platform, use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in medical images. Please visit the company's website at: www.medipattern.com.

B-CAD(TM) and B-CADMRI(TM) are trademarks of The Medipattern Corporation.

Medipattern® is a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Source: Medipattern

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.